Amarna Therapeutics
Leiden, Netherlands· Est.
Amarna Therapeutics has developed a groundbreaking non-immunogenic viral platform to deliver any transgene of choice into humans. It is advancing a pipeline of transformative, potentially curative gene therapies for a range of rare and prevalent diseases, including monogenetic indications, autoimmune diseases and chronic inflammation.
Private Company
Total funding raised: $13.8M
About
Amarna Therapeutics has developed a groundbreaking non-immunogenic viral platform to deliver any transgene of choice into humans. It is advancing a pipeline of transformative, potentially curative gene therapies for a range of rare and prevalent diseases, including monogenetic indications, autoimmune diseases and chronic inflammation.
Drug DeliveryRNA & Gene TherapyViral Technology
Funding History
2Total raised:$13.8M
Series A$12M
Seed$1.8M